Amgen’s combination strategy for Lumakras takes a blow with disappointing checkpoint inhibitor data

The future of one of the most promising KRAS inhibitor combinations is in doubt after Amgen reported disappointing results in previously treated non-small cell lung cancer patients treated with Lumakras plus a checkpoint inhibitor.

At the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC), Amgen Inc. (NASDAQ:AMGN) presented combined data from the Phase Ib CodeBreak-100/101 studies showing its KRAS G12C inhibitor Lumakras sotorasib, plus a PD-1 inhibitor, led to a high rate of serious liver toxicity, with few measures of efficacy improved over Lumakras alone. ...